Comera SPAC Presentation Deck
Caffeine-based Excipient is Optimized Viscosity-Lowering Comera
Beneficial SQore Excipient for Several Biologics
Viscosity (CP)
70
60
50
40
30
20
10
0
0
-Control
-Caffeine
-ArgHCI
--NaCl
Target viscosity
range
25
TM
75 100 125 150
50
infliximab (mg/mL)
Infliximab formulated in a 20 mM phosphate-acetate buffer
at pH 6.0 (control) and in the presence of 75 mM caffeine,
100 mM ArgHCI, or 100 mM NaCl
Viscosity (CP)
70
60
50
40
30
20
10
0
100
Comm. Control
-Comm.-Caffeine
-PBS Control
PBS-Caffeine
125
ň
Target viscosity
range
150 175 200 225
ipilimumab (mg/mL)
Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions" Journal of Pharmaceutical Sciences 110 (2021) 3594-3604 https://doi.org/10.1016/j.xphs.2021.06.030
LIFE SCIENCES
Ipilimumab formulated in Yervoy commercial formulation.
vehicle (Comm.) and PBS with or without 75 mM caffeine
18View entire presentation